The Role of Urine Toxicology in Chronic Opioid Analgesic Therapy

Pain Management Nursing

Volumn 8, Issue 4, 2007, Pages 166-172

  Compton, Peggy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ARTICLE; CHRONIC DISEASE; DRUG MONITORING; HUMAN; METHODOLOGY; NURSING; PAIN; SUBSTANCE ABUSE; TOXICITY TESTING; URINE;

ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG MONITORING; HUMANS; PAIN; SUBSTANCE ABUSE DETECTION; TOXICITY TESTS;

EID: 36148940667     PISSN: 15249042     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmn.2007.06.001     Document Type: Article

References (25)

1. Adams N.J., Plane M.B., Fleming M.F., Mundt M.P., Saunders L.A., and Stauffacher E.A. Opioids and the treatment of chronic pain in a primary care sample. Journal of Pain and Symptom Management 22 (2001) 791-796
2. Antoin H., and Beasley R.D. Opioids for chronic noncancer pain: tailoring the therapy to fit the patient and the pain. Postgraduate Medicine 116 (2004) 37-40 43-44
3. Atluri S., and Sudarshan G. Evaluation of abnormal urine drug screens among patients with chronic nonmalignant pain treated with opioids. Pain Physician 6 (2003) 407-409
4. Butler S.F., Budman S.H., Fernandez K., and Jamison R.N. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 11 (2004) 65-75
5. Center for Substance Abuse Treatment. Improving treatment for drug exposed infants (Treatment improvement protocol (TIP) series 5; DHHS publication no. (SMA) 93-2011) (1993), US Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Services Administration, Rockville MD
6. Christo P.J. Opioid effectiveness and side effects in chronic pain. Anesthesiology Clinics of North America 21 (2003) 699-713
7. Compton P., and Athanasos P. Chronic pain, substance abuse and addiction. The Nursing Clinics of North America 38 (2003) 525-538
8. Federation of State Medical Boards. Model Policy for the Use of Controlled Substances for the Treatment of Pain (2004). http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf May. http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf
9. Fishbain D., Cutler R.B., Rosomoff H.L., Rosomoff R., and Steele R. Validity of self-reported drug use in chronic pain patients. The Clinical Journal of Pain 15 (1999) 184-191
10. Gourlay D.L., Heit H.A., and Almahrez A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Medicine 6 (2005) 107-112
11. Heit H.A., and Gourlay D.L. Urine drug testing in pain medicine. Journal of Pain and Symptom Management 2 (2004) 260-267
12. Kalso E., Edwards J.E., Moore R.A., and McQuay H. Opioids in chronic noncancer pain: a systematic review of efficacy and safety. Pain 112 (2004) 372-380
13. Katz N., and Fanciullo G.J. Role of urine toxicology testing in the management of chronic opioid therapy. The Clinical Journal of Pain 18 (2002) S76-S82
14. Katz N., Sherburne S., Beach M., et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesthesia and Analgesia 97 (2003) 1097-1102
15. Macario A., and Pergolizzi J.V. Urine drug testing in chronic pain patients taking opioids: A clinical practice update. International Journal of Pain Medicine and Palliative Care 4 (2005) 133-139
16. National Institute on Drug Abuse. NIDA InfoFacts: national trends (2004). http://www.nida.nih.gov/infofacts/nationtrends.html Revised. http://www.nida.nih.gov/infofacts/nationtrends.html
17. Passik S.D., Schreiber J., Kirsh K., and Portenoy R.K. A chart review of the ordering and documentation of urine toxicology screens in cancer centers: do they influence patient management?. Journal of Pain and Symptom Management 19 (2000) 40-44
18. Rowbotham M.C., Twilling L., Davies P.S., Reisner L., Taylor K., and Mohr D. Oral opioid therapy for chronic and peripheral and central neuropathic pain. New England Journal of Medicine 348 (2003) 1223-1232
19. Shurman J., and Backer R.C. Focus on urine drug monitoring. Practical Pain Management 6 (2006) 60-67 March
20. Stamer U.M., Bayerer B., and Stuber F. Genetics and variability in opioid response. European Journal of Pain 9 (2005) 101-104 (London, England)
21. Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention, Division of Workplace Programs. Preventing employees from cheating on a urine drug test (2005). http://dwp.samhsa.gov/DrugTesting/Files_Drug_Testing/Federal/Preventing%20Cheaters%20-%20March%202005.pdf March. http://dwp.samhsa.gov/DrugTesting/Files_Drug_Testing/Federal/Preventing%20Cheaters%20-%20March 02005.pdf.
22. Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: national findings (Office of Applied Studies, NSDUH series H-30; DHHS publication no. SMA 06-4194) (2006), Substance Abuse and Mental Health Services Administration, Rockville, MD
23. Substance Abuse and Mental Health Services Administration. Division of Workplace Programs. Drug testing. analytical methods. (2007). http://www.workplace.samhsa.gov/DrugTesting/AnalyticalTesting/index.html http://www.workplace.samhsa.gov/DrugTesting/AnalyticalTesting/index.html. Accessed February 15, 2007
24. Walker J.M., and Hohmann A.G. Cannabinoid mechanisms of pain suppression. Handbook of Experimental Pharmacology 168 (2005) 509-554
25. Wasan A., Michna E., Nedeljkovic S., and Jamison R. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings (2006) Paper presented at American Society of Regional Anesthesia and Pain Medicine 2006 Fall Pain Medicine Meeting and Workshops; November 17, 2006; San Francisco, CA. Abstract A-2.